Navigation Links
Novel Anti-Inflammatories May Offer a New Approach for the Treatment of Stroke
Date:6/25/2012

Los Angeles, California (PRWEB) June 25, 2012

New evidence supporting the potential value of a new type of anti-inflammatory treatment for stroke published last week in the Journal of Cerebral Blood Flow & Metabolism[1]. The new animal study documented more than 40% reduction in stroke size(volume) and neural deficit after treatment with a new TNF-alpha decoy receptor fusion protein, a class of drugs originally developed to treat forms of arthritis. This new study is the latest in a series of animal experiments that goes back more than a decade and follows publication last year of the first human results of the use of a TNF-alpha decoy receptor fusion protein following stroke[2]. The human study, performed at the Institute of Neurological Recovery (INR) in Los Angeles, documented rapid and sustained improvement following treatment at the INR. News reports (see below) have documented the striking potential of the revolutionary new INR treatment approach.

Scientific Background

Stroke produces tissue damage in the brain that causes a detrimental inflammatory response and elevation of the levels of a protein, TNF, that amplifies inflammation. TNF-alpha decoy receptor fusion proteins, such as etanercept, and other biologic TNF inhibitors reduce the damage caused by excess levels of TNF. These new stroke studies suggest that TNF-alpha decoy receptor fusion proteins may have the potential to improve brain function, if administered in ways that allow brain penetration. The INR in Los Angeles and Boca Raton, Florida has pioneered patented [3] anti-TNF methods for treatment of neuroinflammatory disorders, including stroke, Alzheimer's disease, and sciatica. Rapid clinical improvement in brain function in AD following the use of a TNF-alpha decoy receptor fusion protein has been documented on 60 Minutes in Australia in their feature entitled "A New Shot at Life" and in the scientific literature[4].

For further information, please see the website of the Institute of Neurological Recovery: http://www.strokebreakthrough.com

References
1. Sumbria, R.K., et al., Brain protection from stroke with intravenous TNFalpha decoy receptor-Trojan horse fusion protein. J Cereb Blood Flow Metab, 2012.
2. Tobinick, E., Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs, 2011. 25(2): p. 145-55.
3. Issued and pending U.S. and international patents, including, but not limited to U.S. patents 6,982,089; 7,629,311; 7,214,658; and 8,119,127, all assigned to TACT IP, LLC and Australian patent 758,523.
4. For further scientific references please see the INR website Scientific Publications webpage.

© 2012 Institute of Neurological Recovery (INR®)

Read the full story at http://www.prweb.com/releases/2012/6/prweb9633325.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
2. Rutgers team discovers novel approach to stimulate immune cells
3. Novel drug candidates offer new route to controlling inflammation
4. Researchers present new findings for novel pancreatic cancer vaccine
5. Novel biomarkers reveal evidence of radiation exposure
6. VCU Massey Cancer Center sees potential in novel leukemia treatment
7. Study supports urate protection against Parkinsons disease, hints at novel mechanism
8. Novel Natural Sciences Repository Opens Web Portal
9. Experts Offer Advice After Yankee Pitchers Trampoline Injury
10. Mayo Clinic offers newly approved treatment for acid reflux disease
11. Here Are Fruits, Veggies That Offer Best Bang for Your Buck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line ... in Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than ... by government agencies, including NASA. , In 2012, NASA strategically set up 17 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks ... Amica Insurance is sharing tips to make sure your family and vehicle are ... National Safety Council, there may be 439 deaths and an additional 50,500 serious injuries ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at ... daily practices, arts & crafts, discussions, and games all geared towards enhancing your ... have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
(Date:5/26/2016)... ... May 26, 2016 , ... Workrite ... sales leadership and to further develop their rapidly expanding portfolio of customer and ... with a concentration in Marketing and an M.B.A. with concentration in management from ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
Breaking Medicine Technology: